The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
BACKGROUND
Adalimumab induces and maintains remission in adults with Crohn's disease.


OBJECTIVE
To evaluate safety, fistula healing, quality of life and work productivity in adalimumab-treated patients who failed infliximab, including primary nonresponders.


METHODS
After a ≥8-week infliximab washout, patients with moderate-to-severe Crohn's disease received open-label adalimumab as induction (160/80 mg at weeks 0/2) and maintenance (40 mg every other week) therapies. At/after 8 weeks, patients with flare/nonresponse could receive weekly therapy. Minimum study duration was 8 weeks, continuing until the commercial availability of adalimumab for Crohn's disease.


RESULTS
Of 673 patients enrolled, 17% were infliximab primary nonresponders and 83% were initial responders. Three percent of patients had serious infections (mainly abscesses). Complete fistula healing was achieved by 34/88 (39%) patients with baseline fistulas. Improvements in quality of life and work productivity were sustained from week 4 to week 24 for all patients, as well as the subgroup of primary nonresponders.


CONCLUSIONS
Blinded clinical trials have shown adalimumab to be both an effective first-line therapy for anti-TNF-naïve patients and an important treatment option for infliximab-refractory or -intolerant patients. This trial presents open-label experience to support further the safety and effectiveness of adalimumab in patients who failed infliximab therapy, including primary nonresponders (NCT00338650).
Department of Gastroenterology, Mount Sinai Medical Center, New York, NY 10128, USA. simon.lichtiger@mssm.edu
S
S
Lichtiger
D G
DG
Binion
D C
DC
Wolf
D H
DH
Present
A G
AG
Bensimon
E
E
Wu
A P
AP
Yu
A T
AT
Cardoso
J
J
Chao
P M
PM
Mulani
K G
KG
Lomax
J D
JD
Kent
D000038:Abscess; D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D004526:Efficiency; D005260:Female; D005402:Fistula; D006801:Humans; D000069285:Infliximab; D008297:Male; D011788:Quality of Life; D016896:Treatment Outcome; D014937:Work; D014945:Wound Healing / Q000187:drug effects*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab